| 1 |
George JN, Nester CM. Syndromes of thrombotic microangiopathy[J]. N Engl J Med, 2014, 371(7): 654-666.
|
| 2 |
Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management[J]. J Immunol Methods, 2018, 461: 15-22.
|
| 3 |
Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults[J]. Clin J Am Soc Nephrol, 2013, 8(4): 554-562.
|
| 4 |
Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations[J]. World J Nephrol, 2013, 2(3): 56-76.
|
| 5 |
Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Haemolytic uraemic syndrome[J]. Lancet Lond Engl, 2017, 390(10095): 681-696.
|
| 6 |
Cody EM, Dixon BP. Hemolytic uremic syndrome[J]. Pediatr Clin North Am, 2019, 66(1): 235-246.
|
| 7 |
Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome[J]. J Immunol, 2009, 182(10): 6394-6400.
|
| 8 |
Grisaru S, Xie J, Samuel S, et al. Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with shiga toxin-producing Escherichia coli: A systematic review and meta-analysis[J]. JAMA Pediatr, 2017, 171(1): 68-76.
|
| 9 |
Beneke J, Sartison A, Kielstein JT, et al. Clinical and laboratory consequences of platelet transfusion in Shiga toxin-mediated hemolytic uremic syndrome[J]. Transfus Med Rev, 2017, 31(1): 51-55.
|
| 10 |
Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The seventh special issue[J]. J Clin Apheresis, 2016, 31(3): 149-162.
|
| 11 |
Melton-Celsa AR, O′Brien AD. New therapeutic developments against Shiga toxin-producing Escherichia coli[J]. Microbiol Spectr, 2014, 2(5)．
|
| 12 |
Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome[J]. Pediatr Nephrol Berl Ger, 2008, 23(11): 1951-1956.
|
| 13 |
Spinale JM, Ruebner RL, Kaplan BS, et al. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome[J]. Curr Opin Pediatr, 2013, 25(2): 203-208.
|
| 14 |
Cheong HI, Lee BS, Kang HG, et al. Attempted treatment of factor H deficiency by liver transplantation[J]. Pediatr Nephrol Berl Ger, 2004, 19(4): 454-458.
|
| 15 |
Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome[J]. Kidney Int, 2016, 89(3): 701-711.
|
| 16 |
Cornec-Le Gall E, Delmas Y, De Parscau L, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency[J]. Am J Kidney Dis, 2014, 63(1): 119-123.
|
| 17 |
Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS[J]. Blood, 2015, 125(21): 3253-3262.
|
| 18 |
Sharma AP, Greenberg CR, Prasad AN, et al. Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder[J]. Pediatr Nephrol Berl Ger, 2007, 22(12): 2097-2103.
|
| 19 |
Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children[J]. Pediatr Nephrol, 2016, 31(1): 15-39.
|
| 20 |
Vasu S, Wu H, Satoskar A, et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy[J]. Bone Marrow Transplant, 2016, 51(9): 1241-1244.
|
| 21 |
Vergoulas GV. Hemolytic uremic syndrome after renal transplantation[J]. Hippokratia, 2006, 10(3): 99-104.
|
| 22 |
Ruggenenti P. Post-transplant hemolytic-uremic syndrome[J]. Kidney Int, 2002, 62(3): 1093-1104.
|
| 23 |
Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, open-label trial[J]. Am J Kidney Dis, 2016, 68(1): 84-93.
|
| 24 |
Furmańczyk A, Komuda-Leszek E, Durlik M. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation[J]. Ann Transplant, 2009, 14(4): 47-51.
|
| 25 |
Schoettler M, Chonat S, Williams K, et al. Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy[J]. Curr Opin Hematol, 2021, 28(6): 408-416.
|
| 26 |
Igarashi T, Ito S, Sako M, et al. Guidelines for the management and investigation of hemolytic uremic syndrome[J]. Clin Exp Nephrol, 2014, 18(4): 525-557.
|
| 27 |
Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy[J]. Am J Kidney Dis, 2000, 36(4): 844-850.
|
| 28 |
Gloude NJ, Khandelwal P, Luebbering N, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD[J]. Blood, 2017, 130(10): 1259-1266.
|